SOLARA ACTIVE PHA SCI LTDSS

SOLARA ACTIVE PHA SCI LTD

513.20INRR
+2.55+0.50%
At close at Mar 28, 10:27 GMT
INR
No trades
See on Supercharts

SOLARA fundamentals

Key facts

Market capitalization‪24.64 B‬INR
Basic EPS (TTM)−65.52INR
Founded2017
Employees (FY)‪3.57 K‬
CEOSandeep Rao
About

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. Its products include Albendazole, aprepitant, artesunate, brivaracetam, bumetanide, buspiron, cetirizine dihydrochloride, chlorpromazine, cinacalcet hydrochloride, citicoline sodium, colchicine, colesevelam, colestipol, cycloserine, dipyridamole, disulfiram, dolutegravir, edaravone, efinaconazole, ethacrynic acid, etomidate, felbamate, flecainide acetate, flucytosine, gabapentin, hydralazine, ibuprofen, imiquimod, indapamide, lanthanum carbonate octahydrate,levetiracetam, lurasidone, mebendazole, mefenamic acid, mesalamine, mesna, methohexital, methoxsalen, mirabegron, mycophenolate mofetil, naproxen base, nizatidine, obeticholic acid, alanzapine, patiromer sorbitex calcium, pentoxifyline, pitavastatin calcium, posaconazole, praziquantel, ranitidine, rebamipide, rifaximin, rotigotine, safinamide, sapropterin, sevelamer carbonate, succinylcholine, sucroferric oxyhydroxide, sugammadex, tioconazole, tranexamic acid and zileuton. The company was founded on February 23, 2017 and is headquartered in Chennai, India.

Ownership
‪‪48.05 M‬‬
Closely held shares
‪‪26.66 M‬‬ (55.48%)
Free Float shares
‪‪21.39 M‬‬ (44.52%)
Closely held shares
‪‪26.66 M‬‬ (55.48%)
Free Float shares
‪‪21.39 M‬‬ (44.52%)
Capital structure
Market cap
‪‪24.64 B‬‬
Enterprise value
‪‪24.64 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪24.64 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.87x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.87x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−120%‬
‪−80%‬
‪−40%‬
‪0%‬
‪40%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−4.00 B‬‬
‪‪−2.00 B‬‬
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Active Pharma Ingredient
Other
Services
By country
Period: 2023
Asia Pacific
Europe
Rest of the World
North America
Global
South America

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪1.20 B‬‬
‪‪2.40 B‬‬
‪‪3.60 B‬‬
‪‪4.80 B‬‬
Actual
Estimate
Earnings
Next:May 9, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−8.00‬
‪0.00‬
‪8.00‬
‪16.00‬
‪24.00‬
Actual

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.00%
Last payment
Last ex-date
Dividend history
‪0.00%‬
‪0.13%‬
‪0.26%‬
‪0.39%‬
‪0.52%‬
2019
2020
2021
2022
2023
‪0.00‬
‪1.70‬
‪3.40‬
‪5.10‬
‪6.80‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪2.60 B‬‬
‪‪5.20 B‬‬
‪‪7.80 B‬‬
‪‪10.40 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
Assets
Liabilities